KUALA LUMPUR, Malaysia and SINGAPORE, May 30 (Bernama-GLOBE NEWSWIRE) —
• Revenue at RM6.0 billion mark for the first time
• Outstanding growth momentum: revenue up 16%, EBITDA up 19%
• Core profit or PATMI (ex EI) up 22%; Lower headline PATMI due to high base in previous period (Q1 2023) which included one-off gain from sale of non-core asset IMU
“We carried strong growth momentum into Q1 2024, with quarterly revenue hitting the RM6.0 billion mark for the first time. This outstanding performance cut across all our core markets as we took in more patients and provided more complex treatments. This drove core profit, or PATMI (ex EI), higher, even as headline profit was lower because the high base in Q1 2023 included a one-off gain from the sale of IMU.
We continue to focus on providing patients with cutting edge care; for instance, the recent official opening of the region’s first private proton therapy care centre in Singapore further reinforces our position as Asia’s leading Centre of Excellence in comprehensive cancer care.
Overall, we expect favourable tailwinds from secular trends in the countries we operate in, which will underpin our longer-term growth. As we push on with our growth strategy aligned with our “ACE” framework, we are confident that we can generate sustained and sustainable value for all.”
Dr Prem Kumar Nair
Group Chief Executive Officer, IHH Healthcare